m+Medelevator.RU
← Поиск публикаций
Photodermatology, photoimmunology & photomedicine · 2011

Effect of hematoporphyrin monomethyl ether-mediated photodynamic therapy on hypertrophic scar fibroblasts.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Cai Hong, Gu Ying, Sun Qiang, Zeng Jing, Dong Ning, Zhao Guang

Аннотация

BACKGROUND: Clinical studies have demonstrated that photodynamic therapy (PDT) for hyperplastic dermatosis results in a beneficial outcome. Hypertrophic scar (HS) is a pathological process characterized by fibroblastic hyperproliferation. However, it is unclear whether photochemical interactions between PDT and fibroblasts contribute to a beneficial outcome. To investigate the primary photochemical effects of PDT, we studied the efficacy of 630 nm PDT on human fibroblasts from HS using hematoporphyrin monomethyl ether (HMME) as a photosensitizer.

METHODS: Fibroblasts were cultured from nontreated HSs, and cells at passage 4-6 were used for the experiments. Morphological and biochemical changes in fibroblasts were assessed by Hoechst 33258 staining and annexin V-FITC/PI flow cytometry (FCM). Caspase-3 activity assay and immunofluorescence staining were performed to investigate caspase-3 expression in fibroblasts.

RESULTS: The morphological features of cell apoptosis were viewed under a fluorescent microscope by Hoechst 33258 staining. FCM indicated that the apoptotic rate was significantly increased after HMME-PDT, and caspase-3 activity was observed.

CONCLUSIONS: Low-level exposure to 630 nm PDT mediated by HMME appears to induce fibroblast apoptosis and stimulate caspase-3 activation. However, the effect of HMME-PDT on fibroblasts needs further investigation to determine its therapeutic potential for HS.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты